Why This Biotech's Next Chapter Is 'TBD' Amid Deal-Making Dearth

Why This Biotech's Next Chapter Is 'TBD' Amid Deal-Making Dearth

Gilead Sciences' next chapter is still murky, an analyst said Friday, noting a dearth of expected takeovers among biotech stocks during the annual J.P. Morgan Healthcare Conference.